Updated:
Healthcap VIII Advisor
HealthCap, founded by Björn Odlander and Peder Fredriksson in 2001, is a Stockholm-based specialist life-science venture firm with eight fund generations.
Healthcap VIII Advisor
HealthCap launched in 2001 when Björn Odlander and Peder Fredriksson — both physicians with operating and venture backgrounds — structured a dedicated life-science investment platform in Stockholm. The firm's wealth-creation engine ties directly to drug-development outcomes: portfolio companies have produced therapies now treating conditions from genetic diseases to cancer. HealthCap does not disclose third-party capital sources or a single-family-office anchor, operating instead as an independent asset manager raising institutional funds. The strategy spans the full drug-development lifecycle, from preclinical discovery through commercialization. HealthCap vehicles typically target biopharmaceuticals, medical devices, and diagnostics, with a historical emphasis on European innovation. Confirmed portfolio companies include Zealand Pharma and Wilson Therapeutics, the latter acquired by Alexion in 2018 (per public record). The firm co-invests alongside top-tier syndicate partners and has backed multiple assets that achieved regulatory approval in the United States and European Union. Geographic focus centers on the Nordic region and broader Europe, with regulatory pathways frequently extending into North American markets. The firm has raised eight consecutive fund generations, with HealthCap VIII Advisor understood to be the latest management entity. Team size is not publicly confirmed, but the partnership-centered model relies on physician-investors with clinical and scientific training. While no affiliated philanthropic foundation or operating company is publicly disclosed under the same brand, the firm's principals maintain deep academic-medical networks that function as a proprietary sourcing apparatus. As of mid-2025, the specific deployment pace and dry-powder status of Fund VIII are not publicly reported. HealthCap's structural advantage lies in the partnership's clinical fluency: the ability to evaluate molecules not merely as financial bets but as therapeutic candidates with mechanistic plausibility. This dual literacy — scientific and financial — creates a diligence process that generalist healthcare funds cannot easily replicate. The firm's long fund life and willingness to hold assets through clinical inflection points distinguish its architecture from shorter-duration venture models.
General information
Firm type
Private Equity
Year founded
2001
AUM
$100M – $500M (Altss estimate)
Location
Region
Europe
Country
Sweden
City
Stockholm
Corporate office
Stockholm, Sweden
Principals
Björn Odlander
Managing Partner & Co-Founder
Johan Christenson
Partner & Head of HealthCap VIII Advisor
Peder Fredriksson
Managing Partner & Co-Founder
Sector focus
Frequently asked questions
Who runs investment decisions at HealthCap VIII Advisor?
Decisions are driven by the managing partners, including co-founders Björn Odlander and Peder Fredriksson, alongside Partner Johan Christenson. The team operates with a physician-investor model, where partners typically hold both medical and venture backgrounds. Investment committee processes are not publicly detailed, but the concentrated partnership structure means individual partners carry significant influence over therapeutic-area allocations.
How does HealthCap source proprietary deal flow?
HealthCap's sourcing relies heavily on the principals' deep academic-medical networks across the Nordic region and Europe. Because the partners are physicians with direct research-institution ties, the firm often sees preclinical and translational-stage assets before they reach a formal Series A process. This scientific-network advantage functions as the primary proprietary channel, supplemented by syndicate relationships in the US and EU.
Is HealthCap structured as a single family office or an institutional venture firm?
HealthCap is an independent asset manager, not a single-family office. It raises capital across sequential fund generations from institutional limited partners. The firm does not publicly disclose its LP base but operates the HealthCap VIII Advisor entity as part of a managed-account or general-partner structure for its latest fund.
Does HealthCap participate in fund commitments or only direct deals?
HealthCap is a direct investor that builds concentrated portfolios of private biopharma and medtech companies. The firm is not known to allocate to external venture funds as a limited partner. Its model involves taking board seats and actively shaping clinical and regulatory strategy within portfolio companies.
Which sectors does HealthCap explicitly avoid?
HealthCap invests exclusively in human healthcare — biopharmaceuticals, medical devices, and diagnostics — and does not pursue non-healthcare verticals. Within healthcare, the firm has historically avoided healthcare services IT, provider rollups, and payor-side businesses, concentrating instead on therapeutic assets with direct patient impact.
What is HealthCap's known posture on co-investments alongside external GPs?
HealthCap frequently co-invests alongside other specialist life-science investors, with syndicate participation common in larger later-stage rounds. The firm's European-focused funds often partner with US-based crossover and public-market investors when portfolio companies prepare for Nasdaq listings or transatlantic regulatory filings. Terms of co-investment allocations are not publicly disclosed.
How does HealthCap VIII relate to previous HealthCap funds?
HealthCap VIII Advisor is understood to be the management or advisory entity for the firm's eighth fund generation, continuing a strategy that began in 2001. Each fund targets a concentrated portfolio of roughly 15-25 therapeutic companies. The funds typically have long investment periods aligned with drug-development timelines, distinguishing them from generalist tech-venture cycles.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: